科蓝软件：10月24日召开董事会会议

Group 1 - The company Kela Software (SZ 300663) announced that its fourth board meeting was held via telecommunication on October 24, 2025, where it reviewed the proposal for electing members of the fourth board's specialized committees [1] - For the first half of 2025, Kela Software's revenue composition was entirely from the software and information industry, accounting for 100.0% [1] - As of the report date, Kela Software's market capitalization was 8.3 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a robust performance in the biopharmaceutical secondary market [1] - Despite the strong secondary market, the primary market for fundraising in the biopharmaceutical sector is experiencing a cooling trend, as noted by investor Lu Gang from Chuangdong Investment [1]